SCENESSE Treatment in Europe
Filed with ASX · · 2 pages · English
Clinuvel Pharmaceuticals Limited on 6ix
Story so far
Earlier from Clinuvel Pharmaceuticals
- SCENESSE attains breakthrough European Market Authorisation
- US patent for alpha-MSH and analogues
- Patent to assist drug as potential skin cancer preventative
- Clinuvel to evaluate SCENESSE as therapy in vitiligo
- Clinuvel - strategic focus of final regulatory program
Later from Clinuvel Pharmaceuticals
- SCENESSE launched in Europe
- FDA awards SCENESSE Fast Track designation for EPP treatment
- FDA accept SCENESSE clinical data package for NDA submission
- Clinuvel completes combination therapy pre-clinical study
- FDA Schedules Pre-NDA Meeting for SCENESSE
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals